Allogeneic hematopoietic stem cell transplantation (HSCT) is an important therapy for a variety of cancers, including leukemias, lymphomas, and myeloma. Several complications limit its use, including relapse of malignancy, graft-versus-host disease, and prolonged immune depletion caused by the conditioning required for successful transplantation — all of which can lead to increased morbidity and mortality after allo-HSCT. My laboratory studies clinically relevant problems in HSCT and aims to develop novel therapeutic strategies to improve patient outcome.

Learn more
Pictured: Marcel R. M. van den Brink

Marcel R. M. van den Brink, MD, PhD


Research Focus

Physician-scientist Marcel R. M. van den Brink studies the immunology of bone marrow transplantation with a particular focus on intestinal microbiome and strategies to enhance thymus and immune reconstitution


MD, PhD, Universiteit Leiden

Lab Members